Skip to main content
. 2018 Jun 5;18:635. doi: 10.1186/s12885-018-4543-y

Table 1.

Subgroup analyses for the association between BMI and lung cancer risk in never smokers

Categories Subgroups Number of studies RR (95% CI) P value Heterogeneity P-interaction
chi-squared I 2 P-heterogeneity
Obesity 18 0.78(0.65–0.94) 0.01 37.23 54.30% < 0.01
Design Cohort 14 0.74(0.60–0.91) < 0.01 27.83 53.30% 0.01 0.32
Case-control 4 0.97(0.58–1.62) 0.90 8.75 65.70% 0.03
Outcome Incidence 15 0.79(0.63–0.99) 0.04 30.83 54.60% < 0.01 0.74
Mortality 3 0.71(0.45–1.12) 0.14 6.40 68.70% 0.04
Gender Male 5 0.69(0.41–1.15) 0.16 16.58 69.80% < 0.01 0.81
Female 8 0.86(0.72–1.02) 0.08 7.49 19.90% 0.28
Ethnicity Non-Asian 13 0.82(0.64–1.04) 0.10 27.92 57.00% < 0.01 0.51
Asian 5 0.70(0.54–0.91) < 0.01 5.56 28.00% 0.24
Quality High 12 0.76(0.61–0.94) 0.01 27.5 60.00% 0.004 0.72
Low 6 0.84(0.55–1.29) 0.43 9.72 48.60% 0.08
Diagnosis Registry 10 0.77(0.59–1.00) 0.05 22.28 59.60% < 0.01 0.89
Pathology 8 0.79(0.59–1.06) 0.11 14.16 50.60% 0.05
Adjustment for confounders
 Alcohol intake Yes 11 0.83(0.68–1.02) 0.07 18.98 47.30% 0.04 0.49
No 7 0.68(0.45–1.04) 0.07 16.25 63.10% 0.01
 Vegetable/fruit intake Yes 6 0.81(0.58–1.13) 0.22 12.80 60.90% 0.02 0.80
No 12 0.76(0.59–0.97) 0.03 23.41 53.00% 0.02
 Physical activity Yes 9 0.91(0.75–1.11) 0.34 12.18 34.30% 0.14 0.19
No 9 0.67(0.49–0.93) 0.02 18.15 55.90% 0.02
 Medical historya Yes 3 0.78(0.58–0.95) 0.24 35.80 60.90% < 0.01 0.61
No 15 0.90(0.76–1.07) 0.02 0.78 0.00% 0.68
Overweight 15 0.76(0.65–0.87) < 0.01 28.37 50.60% 0.01
Design Cohort 12 0.74(0.62–0.88) < 0.01 27.30 59.70% < 0.01 0.78
Case-control 3 0.80(0.63–1.02) 0.08 1.03 0.00% 0.60
Outcome Incidence 12 0.76(0.64–0.90) < 0.01 16.92 35.00% 0.11 0.93
Mortality 3 0.73(0.53–1.01) 0.06 10.51 81.00% < 0.01
Gender Male 5 0.92(0.62–1.36) 0.68 14.38 72.20% < 0.01 0.44
Female 8 0.82(0.72–0.93) < 0.01 6.52 0.00% 0.48
Ethnicity Non-Asian 11 0.87(0.78–0.97) < 0.01 10.34 3.30% 0.41 0.09
Asian 4 0.61(0.44–0.86) < 0.01 10.87 72.40% 0.01
Quality High 10 0.85(0.77–0.94) < 0.01 9.47 4.90% 0.40 0.32
Low 5 0.70(0.46–1.06) 0.09 13.76 70.90% < 0.01
Diagnosis Registry 8 0.82(0.68–0.98) 0.03 14.38 51.30% 0.04 0.25
Pathology 7 0.68(0.55–0.84) < 0.01 8.74 31.40% 0.19
Adjustment for confounders
 Alcohol intake Yes 11 0.79(0.68–0.92) < 0.01 18.32 45.40% 0.05 0.37
No 4 0.67(0.46–0.97) 0.03 6.36 52.80% 0.10
 Vegetable/fruit intake Yes 5 0.89(0.79–0.99) 0.03 1.46 0.00% 0.83 0.15
No 10 0.68(0.54–0.85) < 0.01 22.26 50.60% < 0.01
 Physical activity Yes 9 0.87(0.77–0.97) 0.02 8.86 9.70% 0.35 0.14
No 6 0.66(0.49–0.88) < 0.01 12.85 61.10% 0.02
 Medical historya Yes 3 0.89(0.79–1.00) 0.05 24.35 0.00% 0.66 0.42
No 12 0.72(0.60–0.87) < 0.01 0.84 50.60% 0.01
Excess weight 23 0.77(0.68–0.88) < 0.01 58.46 62.40% < 0.01
Design Cohort 16 0.80(0.69–0.94) < 0.01 40.07 62.60% < 0.01 0.47
Case-control 7 0.71(0.56–0.91) < 0.01 13.78 56.50% 0.03
Outcome Incidence 19 0.75(0.64–0.88) < 0.01 38.12 52.80% < 0.01 0.60
Mortality 4 0.83(0.63–1.10) 0.19 16.73 82.10% < 0.01
Gender Male 8 0.88(0.70–1.11) 0.29 17.94 55.40% 0.02 0.85
Female 12 0.75(0.62–0.91) < 0.01 28.89 61.90% < 0.01
Ethnicity Non-Asian 14 0.80(0.68–0.95) < 0.01 28.25 54.00% < 0.01 0.66
Asian 9 0.74(0.59–0.94) 0.01 26.05 69.30% < 0.01
Quality High 16 0.83(0.73–0.95) < 0.01 30.06 50.10% 0.01 0.18
Low 7 0.68(0.50–0.90) < 0.01 17.7 66.10% < 0.01
Diagnosis Registry 11 0.88(0.75–1.05) 0.15 24.27 58.80% < 0.01 0.06
Pathology 12 0.68(0.57–0.81) < 0.01 19.97 44.90% 0.05
Adjustment for confounders
 Alcohol intake Yes 12 0.83(0.71–0.97) 0.02 26.74 58.90% 0.01 0.31
No 11 0.71(0.57–0.89) < 0.01 22.73 56.00% < 0.01
 Vegetable/fruit intake Yes 7 0.85(0.69–1.05) 0.13 17.29 57.10% < 0.01 0.37
No 16 0.73(0.62–0.87) < 0.01 34.93 65.30% < 0.01
 Physical activity Yes 9 0.87(0.77–0.99) 0.04 10.14 21.10% 0.26 0.52
No 14 0.75(0.61–0.92) < 0.01 41.15 68.40% < 0.01
 Medical historya Yes 7 0.84(0.68–1.04) 0.11 13.32 55.00% 0.04 0.52
No 16 0.75(0.63–0.89) < 0.01 40.57 63.00% < 0.01
BMI increase per 5 Kg/m2 28 0.89(0.84–0.95) < 0.01 86.44 68.80% < 0.01
Design Cohort 20 0.89(0.82–0.96) < 0.01 58.12 67.30% < 0.01 0.88
Case-control 8 0.90(0.79–1.03) 0.13 24.77 71.70% 0.01
Outcome Incidence 23 0.89(0.83–0.96) < 0.01 65.3 66.30% < 0.01 0.98
Mortality 5 0.89(0.76–1.04) 0.16 20.98 80.90% < 0.01
Gender Male 12 0.96(0.83–1.11) 0.60 28.43 61.30% < 0.01 0.42
Female 13 0.89(0.81–0.97) < 0.01 34.74 65.50% < 0.01
Ethnicity Non-Asian 18 0.91(0.84–0.98) 0.01 47.23 64.00% < 0.01 0.66
Asian 10 0.88(0.78–0.98) 0.03 33.12 72.80% < 0.01
Quality High 20 0.91(0.86–0.98) < 0.01 51.74 63.30% < 0.01 0.39
Low 8 0.85(0.72–1.00) 0.05 26.41 73.50% < 0.01
Diagnosis Registry 15 0.93(0.86–1.00) 0.06 42.41 67.00% < 0.01 0.35
Pathology 13 0.86(0.78–0.95) < 0.01 32.26 62.80% < 0.01
Adjustment for confounders
 Alcohol intake Yes 15 0.89(0.83–0.95) < 0.01 36.97 62.10% < 0.01 0.60
No 13 0.92(0.79–1.07) 0.28 48.42 75.20% < 0.01
 Vegetable/fruit intake Yes 7 0.93(0.84–1.02) 0.13 12.57 52.3% 0.05 0.77
No 21 0.89(0.82–0.96) < 0.01 72.90 72.6% < 0.01
 Physical activity Yes 10 0.92(0.86–0.98) < 0.01 11.33 20.60% 0.25 0.96
No 18 0.90(0.81–0.99) < 0.01 86.44 77.3% < 0.01
 Medical historya Yes 11 0.90(0.83–0.97) < 0.01 29.05 65.60% < 0.01 0.84
No 17 0.88(0.80–0.98) 0.02 56.45 71.70% < 0.01

Note: In the subgroup analyses, amedical history included history of chronic lung disease, history of family lung cancer, diabetes status, and hormone treatment. Other confounders such as total energy intake, environmental status and concomitant medication (use of aspirin and metformin) were not common in original studies; thus, subgroup analyses stratified by them were not performed